Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026
(1998; 113 pages) View the PDF document
Table of Contents
View the documentAbstract
View the documentAcknowledgments
View the documentInformation on authors
View the documentExchange rates used in the report
Open this folder and view contentsChapter 1: Policies for praziquantel*
Open this folder and view contentsChapter 2: Bayer & E. Merck: Discovery and development of praziquantel*
Open this folder and view contentsChapter 3: Shin Poong Pharmaceutical Co.: Process development in the Republic of Korea*
Open this folder and view contentsChapter 4: The Egyptian International Pharmaceutical Industries Co.: Praziquantel formulation*
Open this folder and view contentsChapter 5: The international supply of praziquantel*
Open this folder and view contentsChapter 6: Demand for praziquantel and national distribution*
Open this folder and view contentsChapter 7: Prices and production costs of praziquantel*
View the documentOther documents in the DAP Research Series
View the documentDAP Research Series No. 26
 

International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026

World Health Organization

WHO/DAP/CTD/98.5

Organisation mondiale de la Santé

English only


Distr.: Limited

Edited by
Michael R. Reich

With contributions from:
Michael R. Reich, Ramesh Govindaraj, Karin Dumbaugh,
Bong-min Yang, Agnes Brinkmann, and Sameh El-Saharty

Action Programme on Essential Drugs
Division of Control of Tropical Diseases
January 1998

The research and publication of this report were supported by a grant from the Edna McConnell Clark Foundation

Much research work, particularly in developing countries, at present goes unreported. The reasons for this include the intense competition to publish in the scientific press, and difficulties in matching the research resources of developed countries. The DAP research series was established to provide a forum for the rapid distribution of data and findings relevant to critical areas of drug policy and use. The Action Programme has a firm commitment to national operational research as part of its direct country support. It is also strongly committed to making the findings of such studies widely known and accessible. While every effort is made by the Programme to support studies of the highest possible quality, research skills and resources will vary from country to country. Documents in the DAP research series reflect this variation, and range from reports of very small scale studies, undertaken, with minimal resources, to major global research involving substantive financial, scientific and editorial input.

Note to the readers

The views expressed in this document are solely the responsibility of the authors. The Action Programme on Essential Drugs and the Division of Control of Tropical Diseases are publishing the report as a contribution to the debate on how best to provide access to new and needed drugs.

© Copyright 1998 Harvard University

This document is not issued to the general public, and all rights are reserved by Harvard University.
The document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written permission of Harvard University. No part of this document may be stored in a retrieval system or transmitted in any form or by any means - electronic, mechanical or other - without the prior permission of Harvard University.

The views expressed in documents by named authors are solely the responsibility of those authors.

 

to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: November 5, 2014